share_log

Lifeist Wellness Reports Continuing Improved Trends in Q3 2021

Lifeist Wellness Reports Continuing Improved Trends in Q3 2021

Lifeist Wellness報告2021年第三季度繼續改善趨勢
GlobeNewswire ·  2021/10/29 19:30

Quarterly Financial Metrics

季度財務指標

Depicts quarterly financial metrics
描述季度財務指標

-- Improvement in Key Metrics: Revenue Growth, Adj. Gross Profit, Operating Cashflow
-- Execution in Cannabis as Company Pursues Emerging Nutraceuticals Opportunity

-關鍵指標的改善:收入增長,調整毛利潤,營業現金流
--大麻公司尋求新興的營養食品機會,在大麻執行

TORONTO, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. ("Lifeist" or the "Company") (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: NXTTF), a wellness company that leverages advancements in science and technology to enable you to find your path to wellness, today reported its financial results for the three and nine months ended August 31, 2021. All financial figures are in Canadian dollars unless otherwise indicated.

多倫多,2021年10月29日(環球通訊社)Lifeist Wellness Inc. (“生活家”還是“公司”") (TSXV:LFST)(法蘭克福:M5B)(OTCMKTS:NXTTF),一家利用科技進步讓你找到健康之路的健康公司,今天公佈了截至2021年8月31日的三個月和九個月的財務業績。除非另有説明,所有財務數字均以加元計算。

Third Quarter 2021 Financial Highlights

2021年第三季度財務亮點

  • Gross revenue increased 12% year-over-year to $7.1 million, led by cannabis growth of 34%.
  • Gross profit and margin more than doubled year-over-year to $0.9 million and 15% of Net revenue (23% before inventory adjustment), the fourth consecutive quarterly improvement.
  • EBITDA loss narrowed to $5.4 million compared to $7.3 million in Q3 2020 and $5.9 million in Q2 2021, even with incremental investments into emerging businesses including nutraceuticals.
  • Net cash used in operating activities decreased from $5.7 million in Q2 2021 to $4.9 million in Q3 2021.
  • Inventory management continues to improve with reduced turnover days and lower holdings of inventory.
  • Working capital position of $19.5 million at quarter end remains strong.
  • 毛收入同比增長12%,達到710萬美元,其中大麻增長34%。
  • 毛利和利潤率同比增長逾一倍,達到90萬美元和淨營收的15%(庫存調整前為23%),為連續第四個季度改善。
  • EBITDA虧損從2020年第三季度的730萬美元和2021年第二季度的590萬美元收窄至540萬美元,即使對包括營養食品在內的新興業務進行了增量投資。
  • 用於經營活動的淨現金從2021年第二季度的570萬美元下降到2021年第三季度的490萬美元。
  • 庫存管理繼續改善,週轉天數減少,庫存持有量減少。
  • 截至季度末,營運資本狀況保持強勁,為1950萬美元。

"Our improved third quarter results reflect ongoing positive trends: higher revenue, lower costs, and better cash flow," said Meni Morim, CEO of Lifeist. "We are seeing the early payoff from our focus on where we can deliver more profitable growth, operate more efficiently, and optimize working capital within our current portfolio of businesses while we invest in the future. We are pressing forward with our plans to develop nutraceuticals products with a new business unit launching this quarter, enabling Lifeist to transition to sustainable profitability. The improved performance in our cannabis business while we invest in this emerging opportunity reinforces our confidence in our strategy and we expect continued top-line growth and improvements in profitability as we navigate through this transformation. Overall, there has been a significant amount of work done across the Company laying the foundations for growth as we continue our company's evolution to wellness."

Lifeist首席執行官梅尼·莫里姆(Meni Morim)表示:“我們第三季度業績的改善反映了持續的積極趨勢:更高的收入、更低的成本和更好的現金流。”我們看到,在我們投資未來的同時,我們專注於在我們現有的業務組合中實現更有利可圖的增長,更有效地運營,並優化營運資本,這將帶來早期的回報。我們正在推進開發營養食品產品的計劃,本季度將推出一個新的業務部門,使Lifeist能夠過渡到可持續的盈利能力。在我們投資於這一新興機會的同時,我們的大麻業務表現有所改善,這增強了我們對我們戰略的信心,我們預計在我們完成這一轉型的過程中,收入將繼續增長,盈利能力也將有所改善。總體而言,在我們公司繼續向健康發展的過程中,整個公司做了大量的工作,為增長奠定了基礎。“

Added Mr. Morim, "In particular, the financial turnaround is being led by our cannabis subsidiary, CannMart, Inc., which is experiencing strong demand for its portfolio of products from consumers, retailers and provincial wholesalers across Canada as evidenced by the 34% growth in cannabis revenue in the quarter. What makes CannMart unique is its ability to bring brands to market quickly, whether it be via the increasing number of master distribution agreements that we are signing where we act as the middleman, or via the expansion of our product portfolio with the launch of our limited-edition SKUs made at our subsidiary CannMart Labs's state-of-the-art BHO extraction facility."

莫林先生補充説:“尤其是,我們的大麻子公司CannMart公司正在帶領財務好轉,該公司正經歷着加拿大各地消費者、零售商和省級批發商對其產品組合的強勁需求,本季度大麻收入增長了34%就是明證。坎馬特的獨特之處在於它能夠迅速將品牌推向市場,無論是通過我們作為中間人簽署的越來越多的主分銷協議,還是通過推出我們子公司坎馬特實驗室最先進的BHO提取設施生產的限量版SKU來擴大我們的產品組合。“

Operational Highlights

運營亮點

  • CannMart Inc. continues to enter into partnerships with third parties to be their wholesale and logistics partner in order to take advantage of the trend where Canadian licensed producers (LPs) and manufacturers are looking to outsource parts of their operations that are not core. During the third quarter, CannMart Inc. signed Master Distribution Agreements with several companies including with Rapid Dose Therapeutics Corp. ("RDT") (CSE: DOSE) to exclusively distribute RDT's innovative RDT branded products across Canada.
  • CannMart Inc. received its first purchase orders from the provinces of Manitoba, and Saskatchewan for its 2.0 consumer-focused recreational house brand "Roilty" concentrates.
  • As part of its focus on the broader wellness space, the Company changed its corporate name from Namaste Technologies Inc. to Lifeist Wellness Inc. effective September 9, 2021, and changed its stock ticker symbol on the TSXV to its current symbol "LFST".
  • Lifeist continues to look for ways to operate more efficiently, including subleasing its former Toronto office headquarters which is expected to generate annual run rate savings of approximately $138,000 until expiry of its lease in October 2024, as well as consolidating headcount, software and marketing costs across divisions in order to reduce costs and reallocate resources more efficiently across the Company, and implementing inventory control measures on the cannabis business to reduce carrying costs.
  • CannMart Inc.繼續與第三方建立夥伴關係,成為他們的批發和物流合作伙伴,以便利用加拿大特許生產商(LP)和製造商尋求外包其非核心業務部分的趨勢。第三季度,CannMart公司與包括快速劑量治療公司(“RDT”)(CSE:DOG)在內的幾家公司簽署了主分銷協議,在加拿大獨家經銷RDT公司的創新RDT品牌產品。
  • CannMart Inc.收到了來自馬尼託巴省和薩斯喀徹温省的第一批訂單,購買其2.0消費者為重點的休閒住宅品牌“Roilty”濃縮品。
  • 作為專注於更廣泛的健康領域的一部分,該公司從Namaste Technologies Inc.更名為Lifeist Wellness Inc.,從2021年9月9日起生效,並將其在多倫多證券交易所的股票代碼改為目前的代碼“LFST”。
  • Lifeist繼續尋找提高運營效率的方法,包括轉租其前多倫多辦事處總部,預計在2024年10月租約到期之前,該總部每年將節省約138,000美元,並整合各部門的員工、軟件和營銷成本,以降低成本,並在整個公司更有效地重新分配資源,以及對大麻業務實施庫存控制措施,以降低運輸成本。

Financial Summary of Q3 2021 and Comparative Periods

2021年第三季度財務摘要及比較期間

  Q3 2020 Q2 2021 Q3 2021   YTD 2020 YTD 2021
Gross revenue $ 6,281,875   $ 6,266,808   $ 7,067,091     $ 19,099,640   $ 19,482,586  
Net revenue $ 5,684,847   $ 5,275,779   $ 5,787,750     $ 17,918,313   $ 16,578,264  
Gross profit (before inventory adjustment) $ 552,381   $ 753,613   $ 1,305,806     $ 1,915,159   $ 2,513,468  
Gross profit % (before inventory adjustment)   10 %   14 %   23 %     11 %   15 %
Net loss $ (7,833,495 ) $ (6,369,642 ) $ (6,053,422 )   $ (20,067,533 ) $ (19,804,507 )
Net loss per share (basic and diluted) $ (0.02 ) $ (0.02 ) $ (0.02 )   $ (0.06 ) $ (0.06 )
Total assets $ 46,481,236   $ 46,328,594   $ 41,221,145     $ 46,481,236   $ 41,221,145  
Cash used in operating activities $ (5,262,843 ) $ (5,674,692 ) $ (4,909,845 )   $ (20,506,989 ) $ (13,051,970 )
Q3 2020 Q2 2021 Q3 2021 YTD 2020年 2021年年初
毛收入 $ 6,281,875 $ 6,266,808 $ 7,067,091 $ 19,099,640 $ 19,482,586
淨收入 $ 5,684,847 $ 5,275,779 $ 5,787,750 $ 17,918,313 $ 16,578,264
毛利(存貨調整前) $ 552,381 $ 753,613 $ 1,305,806 $ 1,915,159 $ 2,513,468
毛利%(存貨調整前) 10 % 14 % 23 % 11 % 15 %
淨損失 $ (7,833,495 ) $ (6,369,642 ) $ (6,053,422 ) $ (20,067,533 ) $ (19,804,507 )
每股淨虧損(基本和稀釋後) $ (0.02 ) $ (0.02 ) $ (0.02 ) $ (0.06 ) $ (0.06 )
總資產 $ 46,481,236 $ 46,328,594 $ 41,221,145 $ 46,481,236 $ 41,221,145
用於經營活動的現金 $ (5,262,843 ) $ (5,674,692 ) $ (4,909,845 ) $ (20,506,989 ) $ (13,051,970 )

Gross revenue increased 12% to $7.1 million in Q3 2021, as compared to $6.3 million in Q3 2020. This growth was driven by the Company's cannabis business which increased 34% due to increased volume of orders from provincial customers, enhanced product selection and a new dropship revenue stream added in Q3 2021. In addition, SaaS revenue increased 9% as compared to Q3 2020.

2021年第三季度毛收入增長12%,達到710萬美元,而2020年第三季度為630萬美元。這一增長是由該公司的大麻業務推動的,該業務增長了34%,這是由於來自省級客户的訂單量增加、產品選擇增強以及2021年第三季度增加了新的託運收入流。此外,與2020年第三季度相比,SaaS收入增長了9%。

Adjusted gross margin, before inventory write-down, was 23% of Net revenue in Q3 2021 compared to 10% in Q3 2020 and 14% in Q2 2021. The 1,300-basis point improvement year-over-year was due to improved production efficiencies across all segments.

2021年第三季度,庫存減記前的調整後毛利率為淨收入的23%,而2020年第三季度和2021年第二季度分別為10%和14%。同比增長1300個基點是由於所有細分市場的生產效率都有所提高。

EBITDA loss narrowed to $5.4 million in Q3 2021 compared to $7.3 million in Q3 2020, due to improved performance across most business units. The reduced EBITDA loss was net of approximately $1 million of investments in emerging businesses including CannMart Labs and nutraceuticals.

由於大多數業務部門的業績改善,2021年第三季度EBITDA虧損從2020年第三季度的730萬美元收窄至540萬美元。減少的EBITDA虧損是扣除對新興業務的約100萬美元投資後的淨額,這些投資包括坎瑪實驗室(CannMart Labs)和營養食品。

Net loss in Q3 2021 was $6.1 million, largely impacted by increased Salaries and Selling and Marketing costs, as a result of a strategic investment in the growth of core business segments as well as an upfront investment in the nutraceutical segment.

2021年第三季度淨虧損為610萬美元,主要受工資以及銷售和營銷成本增加的影響,這是對核心業務部門增長的戰略投資以及對營養食品部門的前期投資。

Balance Sheet and Cash Flow

資產負債表和現金流

Cash and cash equivalents were $17.9 million as of August 31, 2021, compared to $23.0 million as of May 31, 2021, which is sufficient to fund planned growth initiatives.

截至2021年8月31日,現金和現金等價物為1790萬美元,而截至2021年5月31日為2300萬美元,足以為計劃中的增長計劃提供資金。

Demonstrating continued improved inventory management practices, inventories decreased to $4.9 million compared to $5.2 million in Q2 2021 and $6.0 million in Q1 2021.

庫存管理實踐不斷改善,庫存從2021年第二季度的520萬美元和2021年第一季度的600萬美元降至490萬美元。

Net cash used in operations was $4.9 million for the quarter. This is the third consecutive quarter in which the Company demonstrated EBITDA loss improvements.

該季度運營中使用的淨現金為490萬美元。這是該公司連續第三個季度表現出EBITDA虧損的改善。

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6542334e-7ea0-427f-8ea9-a73412adcc5d

有關這一聲明的圖片,請訪問https://www.globenewswire.com/NewsRoom/AttachmentNg/6542334e-7ea0-427f-8ea9-a73412adcc5d。

Additional Information

附加信息

Financial results and analysis are available on Lifeist's website (www.lifeist.com) and SEDAR (www.sedar.com).

財務結果和分析可在Lifeist的網站(www.life ist.com)和SEDAR(www.sedar.com)上查閲。

About Lifeist Wellness Inc.

關於Lifeist Wellness Inc.

Lifeist is at the forefront of the post-pandemic wellness revolution requiring smart solutions. Lifeist is a portfolio wellness company leveraging advancements in science and technology to enable you to find your path to wellness. Portfolio business units include: CannMart.com that provides Canadian medical customers with a diverse selection of cannabis products from a multitude of federally licensed cultivators and its U.S. customers with access to hemp-derived CBD and smoking accessories; and CannMart's Canadian recreational cannabis distribution business facilitating recreational sales to a number of provincial government control boards. The Company is set to launch a new nutraceuticals division in the fourth quarter with disruptive products in wellness. For more information, visit www.lifeist.com, Cannmart.com and everyonedoesit.co.uk.

Lifeist處於大流行後健康革命的前沿,需要智能的解決方案。Lifeist是一家健康投資組合公司,利用科學技術的進步讓你找到健康之路。CannMart.com的業務組合包括:CannMart.com,該網站向加拿大醫療客户提供來自聯邦政府許可的大量大麻種植者和美國客户的多樣化大麻產品,使其能夠獲得大麻衍生的CBD和吸煙輔料;以及CannMart的加拿大娛樂大麻分銷業務,該業務為向多個省政府管制委員會提供娛樂銷售提供便利。該公司將在第四季度推出一個新的營養食品部門,生產具有破壞性的健康產品。欲瞭解更多信息,請訪問www.Lifeist.com、Cannmart.com和每個人都這樣做。

Contacts

聯繫人

Lifeist Wellness Inc.
Meni Morim, CEO
Matt Chesler, CFA, Investor Relations
Ph: 647-362-0390
Email: ir@lifeist.com

Lifeist Wellness Inc.
梅尼·莫里姆(Meni Morim),首席執行官
馬特·切斯勒(Matt Chesler),CFA,投資者關係
電話:647-362-0390
電子郵件:ir@lifist.com

Non-IFRS Financial Measures

非國際財務報告準則財務衡量標準

Management evaluates the Company's performance using a variety of measures, including "Net loss before income tax, depreciation and amortization" and "Adjusted EBITDA". The non-IFRS measures discussed below should not be considered as an alternative to or to be more meaningful than revenue or net loss. These measures do not have a standardized meaning prescribed by IFRS and therefore they may not be comparable to similarly titled measures presented by other publicly traded companies and should not be construed as an alternative to other financial measures determined in accordance with IFRS.

管理層使用各種衡量標準來評估公司的業績,包括“扣除所得税、折舊和攤銷前的淨虧損”和“調整後的EBITDA”。下文討論的非國際財務報告準則計量不應被視為收入或淨虧損的替代措施或比收入或淨虧損更有意義。這些措施沒有國際財務報告準則規定的標準化含義,因此它們可能無法與其他上市公司提出的同名措施相提並論,不應被解釋為根據國際財務報告準則確定的其他財務措施的替代方案。

The Company believes these non-IFRS financial measures provide useful information to both management and investors in measuring the financial performance and financial condition of the Company.

該公司相信,這些非國際財務報告準則財務指標在衡量公司的財務業績和財務狀況時為管理層和投資者提供了有用的信息。

Management uses these and other non-IFRS financial measures to exclude the impact of certain expenses and income that must be recognized under IFRS when analyzing consolidated underlying operating performance, as the excluded items are not necessarily reflective of the Company's underlying operating performance and make comparisons of underlying financial performance between periods difficult. From time to time, the Company may exclude additional items if it believes doing so would result in a more effective analysis of underlying operating performance. The exclusion of certain items does not imply that they are non-recurring.

管理層使用這些和其他非IFRS財務指標來排除在分析綜合基本經營業績時必須根據IFRS確認的某些支出和收入的影響,因為被排除的項目不一定反映公司的基本經營業績,並使不同時期的基本財務業績難以比較。如果公司認為這樣做可以更有效地分析潛在的經營業績,它可能會不時地排除額外的項目。排除某些項目並不意味着它們是非經常性的。

(i) Current and deferred income taxes, depreciation and amortization, and share-based compensation were excluded from the Adjusted EBITDA calculation as they do not represent cash expenditures.
(ii) Other income consisting of gain on disposal of subsidiary, interest income, realized gain on disposition of AFS investments, unrealized gain on derivatives and other miscellaneous non-recurring income were excluded from Adjusted EBITDA calculation.
(iii) Non-recurring costs related to restructuring and legacy issues were excluded from Adjusted EBITDA calculation.
(iv) Impairment loss relating to goodwill, customer list, domains and brand names were excluded from Adjusted EBITDA calculation.
(v) Impairment loss relating to receivable is a provision for expected credit loss to an associate and was excluded from Adjusted EBITDA calculation.
(vi) Share of associates loss, net of tax, is excluded due to lack of control.

(I)調整後的EBITDA計算不包括當期和遞延所得税、折舊和攤銷以及基於股份的薪酬,因為它們不代表現金支出。
(Ii)其他收入,包括出售附屬公司的收益、利息收入、出售AFS投資的已實現收益、衍生工具未實現收益和其他雜項非經常性收入,均不包括在調整後EBITDA計算中。
(Iii)調整後EBITDA計算不包括與重組和遺留問題有關的非經常性成本。
(Iv)經調整EBITDA計算不包括與商譽、客户名單、域名及品牌名稱有關的減值虧損。
(V)與應收賬款有關的減值虧損為聯營公司的預期信貸虧損撥備,未計入經調整EBITDA計算。
(Vi)由於缺乏控制,扣除税項後的聯營公司虧損份額不包括在內。

Forward-Looking Information

前瞻性信息

This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as "may", "expect", "likely", "should", "would", "plan", "anticipate", "intend", "potential", "proposed", "estimate", "believe" or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions "may" or "will" happen.

本新聞稿包含適用證券法所指的“前瞻性信息”。本文中包含的所有非歷史性陳述均含有前瞻性信息。前瞻性信息可以通過諸如“可能”、“預期”、“可能”、“應該”、“將”、“計劃”、“預期”、“打算”、“潛在”、“建議”、“估計”、“相信”或這些術語的否定或其他類似的詞語、表達及其語法變體,或某些事件或條件“可能”或“將”發生的陳述來識別。

The forward-looking information contained herein, including the Company's continued evolution into a wellness company, the anticipated launch of a nutraceutical division in the fourth quarter of 2021 and certain actions the Company expects to take to operate more efficiently are only predictions and are made as of the date of this news release. Various assumptions were used in developing the forward-looking information throughout this news release which management believed to be reasonable at the time such statements were made, including expectations that the introduction of a new nutraceutical division, products and brands will generate additional revenue, management's perceptions of Lifeist's standing in the online marketplace for wellness, cannabis and related products and accessories, Lifeist's beliefs regarding the expected demand for wellness, cannabis and related products and accessories and the expected growth of that market, results of operations, operational matters, historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation: unforeseen developments that would delay the Company's ability to launch its nutraceutical division as anticipated an in a timely manner, risks relating to the Company's ability to develop and execute its business strategy and to implement its various cost cutting measures as anticipated and in a timely manner and the benefits realizable therefrom, risks specifically related to the Company's operations, and risks relating to the Company's ability to successfully operate everywhere in a virtual environment. Additional risk factors can also be found in the Company's current MD&A and annual information form, both of which have been filed under the Company's SEDAR profile at www.sedar.com. Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

本文中包含的前瞻性信息,包括公司繼續發展成為一家健康公司、預計在2021年第四季度成立營養食品部門以及公司預計將採取某些行動以提高運營效率,這些信息只是預測,是在本新聞稿發佈之日作出的。本新聞稿中使用了各種假設來開發前瞻性信息,管理層認為這些信息在做出這些聲明時是合理的,包括推出一個新的營養食品部門、產品和品牌將產生額外收入的預期、管理層對Lifeist在健康、大麻和相關產品和配件在線市場的地位的看法、Lifeist對健康、大麻和相關產品和配件的預期需求以及該市場的預期增長、運營結果、運營事項、歷史趨勢、當前狀況的看法以及其他被認為在這種情況下合適的考慮因素。雖然根據管理層目前掌握的信息,我們認為這些假設是合理的,但不能保證這樣的預期將被證明是正確的。就其性質而言,前瞻性信息受到固有風險和不確定性的影響,這些風險和不確定性可能是一般性或具體性的,導致預期、預測或結論被證明不準確,假設可能不正確,目標、戰略目標和優先事項無法實現。各種因素,包括已知和未知的風險,其中許多是我們無法控制的, 可能導致實際結果與本新聞稿中的前瞻性信息大不相同。這些因素包括但不限於:可能導致公司無法按預期和及時推出其營養食品部門的不可預見的事態發展;與公司制定和執行其業務戰略以及按預期及時實施各種成本削減措施的能力相關的風險以及由此可實現的收益;與公司業務具體相關的風險;以及與公司在虛擬環境中在任何地方成功運營的能力相關的風險。其他風險因素還可以在公司目前的MD&A和年度信息表中找到,這兩份表格都已在公司的SEDAR簡介中提交,網址是www.sedar.com。提醒讀者不要過度依賴前瞻性信息。除非適用法律要求,否則公司不承擔更新或修改任何前瞻性信息的義務,無論是由於新信息、未來事件還是其他原因。本新聞稿中包含的前瞻性陳述明確受本警告性聲明的限制。

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

多倫多證券交易所風險交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任,也不以任何方式批准或不批准本新聞稿的內容。

Source: Lifeist Wellness Inc.

來源:Lifeist Wellness Inc.


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論